AU5140993A - Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith - Google Patents

Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith

Info

Publication number
AU5140993A
AU5140993A AU51409/93A AU5140993A AU5140993A AU 5140993 A AU5140993 A AU 5140993A AU 51409/93 A AU51409/93 A AU 51409/93A AU 5140993 A AU5140993 A AU 5140993A AU 5140993 A AU5140993 A AU 5140993A
Authority
AU
Australia
Prior art keywords
methods
acid derivatives
fungal growth
treating hypercholesterolemia
zaragozic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51409/93A
Inventor
Byron H. Arison
Shieh-Shung Tom Chen
George A. Doss
Leeyuan Huang
John G. Macconnell
Richard L. Monaghan
Laszlo R. Treiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/979,559 external-priority patent/US5359096A/en
Priority claimed from US07/982,163 external-priority patent/US5317031A/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU5140993A publication Critical patent/AU5140993A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU51409/93A 1992-10-06 1993-09-27 Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith Abandoned AU5140993A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US957350 1978-11-03
US95735092A 1992-10-06 1992-10-06
US96315392A 1992-10-19 1992-10-19
US963153 1992-10-19
US07/979,559 US5359096A (en) 1991-06-14 1992-11-20 Cholesterol lowering compounds
US979559 1992-11-20
US07/982,163 US5317031A (en) 1992-10-19 1992-11-24 Cholesterol lowering compounds
US982163 1992-11-24
PCT/US1993/009144 WO1994007485A1 (en) 1992-10-06 1993-09-27 Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith

Publications (1)

Publication Number Publication Date
AU5140993A true AU5140993A (en) 1994-04-26

Family

ID=27506035

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51409/93A Abandoned AU5140993A (en) 1992-10-06 1993-09-27 Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith

Country Status (2)

Country Link
AU (1) AU5140993A (en)
WO (1) WO1994007485A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2185441A1 (en) * 1994-03-15 1995-09-21 Michael D. Lewis Isoprenyl transferase inhibitors
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
AR054368A1 (en) * 2005-06-01 2007-06-20 Takeda Pharmaceutical METHOD TO TREAT HYPERLIPIDEMIA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055487A (en) * 1990-03-21 1991-10-08 Merck & Co., Inc. Novel anti-fungal compounds
US5053425A (en) * 1990-03-21 1991-10-01 Merck & Co., Inc. Novel anti-fungal compounds
US5096923A (en) * 1990-03-21 1992-03-17 Merck & Co., Inc. Novel squalene synthetase inhibitors
US5132320A (en) * 1990-03-21 1992-07-21 Merck & Co., Inc. Squalene synthetase inhibitors
US5102907A (en) * 1990-09-13 1992-04-07 Merck & Co., Inc. Novel squalene synthetase inhibitors
WO1992012160A1 (en) * 1991-01-09 1992-07-23 Glaxo Group Limited Bridged cyclic ketal derivatives

Also Published As

Publication number Publication date
WO1994007485A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
AU7689791A (en) Drug-free method for treatment of alopecia
AU4479093A (en) External male catheter, applicator and method of use
AU6710598A (en) Improved methods for the determination and adjustment of prolactin daily rhythms
EP0678031A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof.
AU3572493A (en) Histamine derivatives and methods for their use as immunomodulators
AU1115095A (en) Treatment of cellulose
AU8806491A (en) Active fragments of fibroblast growth factor
AU5960394A (en) Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
AU7626991A (en) Combination of pravastatin and fibric acid derivative, and method for treating dyslipidemia using such combination
AU3328693A (en) Treatment of fungal infections
AU4829793A (en) Quinazoline derivatives
AU4790893A (en) Pyridylethoxy-, pyridylethylamino-, and pyridylpropyl-derivatives of quinoline and quinazoline as insecticides and fungicides
AU2685892A (en) Method of treating blood
AU5184393A (en) Substituted derivatives of diaminophthalimide
AU4954193A (en) Fullerene derivatives, method of synthesizing them and their use
AU3973793A (en) Method of treating cancer
AU5140993A (en) Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith
AU4220193A (en) Deazaaminopterins for treatment of inflammation
AU4172693A (en) Novel thienothiazine derivatives, process for their preparation and their use
AU4805093A (en) Methods for treatment of enzyme preparations
AU1314995A (en) Aminosulphonyl-phenyl-1h-pyrrole derivatives, method of their preparation and their use
AU5340594A (en) Skin treatment
AU1028892A (en) Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
AU7770991A (en) Method and composition for the treatment of cancer
AU642772B2 (en) Inhibitors for the formation of tumor necrosis factor, processes for the preparation thereof and the use thereof